<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05072067</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A01562-39</org_study_id>
    <nct_id>NCT05072067</nct_id>
  </id_info>
  <brief_title>EFFICACY OF THE SLEEVE GASTROPLASTY WITH THE ENDOSCOPIC SYSTEM OVERSTICH SX ON WEIGHT LOSS AND REDUCTION OF CO-MORBIDITY FOR OBESE PATIENTS</brief_title>
  <acronym>SLEEVE</acronym>
  <official_title>EFFICACY OF THE SLEEVE GASTROPLASTY WITH THE ENDOSCOPIC SYSTEM OVERSTICH SX ON WEIGHT LOSS AND REDUCTION OF CO-MORBIDITY FOR OBESE PATIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinique du Trocadéro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinique du Trocadéro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The OverStitch ™ Sx System (Apollo Endosurgery Inc., Austin, Tx, Usa) is a new generation of&#xD;
      endoscopic suturing device. It is inserted into an endoscope allowing the approximation of&#xD;
      Luc Karsentys soft tissue by placement of sutures. It is as effective a suture system as a&#xD;
      surgical system. The OverStitch ™ Sx allows suturing in the upper and lower GI with a&#xD;
      flexible single channel endoscope. Previously, the ™ Overstich was only compatible with an&#xD;
      Olympus dual channel endoscope.&#xD;
&#xD;
      Thus, a wide range of interventions are possible, including gastric endoplastic sleeve (ESG),&#xD;
      RYGB revision, anastomotic fistula repair and / or sleeve revision. In each of these&#xD;
      indications, the OverStitch (OverStitch) ™ system has shown its effectiveness and safety.&#xD;
&#xD;
      The OverStitch Endoscopic ™ Suture System allows the entire digestive wall to be sutured&#xD;
      through a flexible endoscope. Thus, a wide range of interventions are possible, including&#xD;
      gastric pocket repair after gastric bypass surgery, anastomotic fistula repair, endoscopic&#xD;
      treatment of digestive perforation, and endoscopic sleeve surgery. In each of these&#xD;
      indications, the OverStitch system has demonstrated its effectiveness and safety. But this&#xD;
      technique is recent, especially in France. In addition, no data has yet been released&#xD;
      regarding the new Overstitch ™ Sx device compatible with all single channel endoscopes.&#xD;
&#xD;
      An observational study including patients in French centers that are experts in therapeutic&#xD;
      endoscopy seems essential to us to better assess this new device and this new technique in&#xD;
      practice&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>For the endoscopic sleeve: by the rate of patients with a percentage of total weight lost</measure>
    <time_frame>6 MONTHS</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>For the endoscopic sleeve: by the rate of patients with a percentage of total weight lost</measure>
    <time_frame>12 MONTHS</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of safety Immediate morbidity</measure>
    <time_frame>DAY 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For sleeve revision, by the rate of patients with a percentage of total weight lost</measure>
    <time_frame>6 MONTHS</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>For sleeve revision, by the rate of patients with a percentage of total weight lost</measure>
    <time_frame>12 MONTHS</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>OBESE PATIENT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OverStitch™ Sx with a Single channel endoscop CO2 Insufflation, patient on decubitus dorsal, with intubate 3 to 7 sutures, from the antral ogiv to the cardia are done</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>the sleeve gastroplasty with the endoscopic system Overstich SX</intervention_name>
    <description>the sleeve gastroplasty with the endoscopic system Overstich SX</description>
    <arm_group_label>OBESE PATIENT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18, male or female&#xD;
&#xD;
          -  Patient with obesity with a BMI&gt; 30 or BMI&gt; 40 (if surgery contraindicated or refused&#xD;
             by the patient)&#xD;
&#xD;
          -  Patient with a weight gain after sleeve gastroplasty or sleeve gastrectomy&#xD;
&#xD;
          -  Informed and written consent of the patient obtained&#xD;
&#xD;
          -  Complete clinical examination&#xD;
&#xD;
          -  Lack of participation in another clinical study&#xD;
&#xD;
          -  Patient able to follow, understand the study and answer the questionnaire&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Haemorrhagic disease, haemostasis and coagulation disorder and platelets &lt;60000 /&#xD;
             mm3).&#xD;
&#xD;
          -  Breastfeeding women&#xD;
&#xD;
          -  Toxicomany, alcoolism&#xD;
&#xD;
          -  Patient known for gastric lesion requiring surveillance or familial history of gastric&#xD;
             neoplasia&#xD;
&#xD;
          -  Hiatus hernia&gt; 4 cm high&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BOUCHRA BENKESSOU, Project Manager</last_name>
    <phone>0764486016</phone>
    <email>b.benkessou@cliniques-bltparis.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>VIANNA COSTIL, DOCTOR</last_name>
    <email>vianna@costil.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Du Trocadero</name>
      <address>
        <city>Paris</city>
        <zip>75016</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>BOUCHRA BENKESSOU</last_name>
      <phone>0764486016</phone>
      <email>b.benkessou@cliniques-bltparis.fr</email>
    </contact>
    <investigator>
      <last_name>VIANNA COSTIL, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

